Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Receivables: 2021-2024

Historic Receivables for Keros Therapeutics (KROS) over the last 3 years, with Dec 2024 value amounting to $2.7 million.

  • Keros Therapeutics' Receivables rose 800.00% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.3 million, marking a year-over-year increase of 5069.65%. This contributed to the annual value of $2.7 million for FY2024, which is 1817.48% up from last year.
  • As of FY2024, Keros Therapeutics' Receivables stood at $2.7 million, which was up 1,817.48% from $143,000 recorded in FY2023.
  • Keros Therapeutics' Receivables' 5-year high stood at $18.0 million during FY2021, with a 5-year trough of $143,000 in FY2023.
  • Moreover, its 2-year median value for Receivables was $1.4 million (2023), whereas its average is $1.4 million.
  • Data for Keros Therapeutics' Receivables shows a peak YoY skyrocketed of 1,817.48% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Keros Therapeutics' Receivables stood at $18.0 million in 2021, then reached $143,000 in 2023, then surged by 1,817.48% to $2.7 million in 2024.